Expert Interview
Discussing MediciNova’s MN-166 for the treatment of ARDS, sepsis, and cytokine release syndrome, following IV results
Ticker(s): MNOVAn intensivist with experience in treating ARDS, sepsis, and cytokine release syndrome.
Please describe your practice as a clinician,how many patients with either ARDS sepsis, and cytokine release syndrome do you see on a yearly basis in the ICU? Can you describe the standard of care, and take us through the most promising upcoming treatments?
How much of an unmet need is there in the intensive care space, specifically, in preventing ARDS, sepsis, and cytokine release syndrome?
How efficient do you think the mechanism of action of small molecule glial attenuators are, in suppressing pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6, and upregulating the anti-inflammatory cytokine IL-10? How important are those parameters this in the ICU unit. when treating ARDS, sepsis, and cytokine release syndrome?
Could you please discuss the safety profile of the drug, compared to standard of care?
Can you please discuss the acute and severe clinical settings that require fast bioavailability? How would MN-166 IV formulation fit in that area?
How likely would you be to use MN-166 in the ICU, judging by the clinical trial results to date?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
